Detalles de la búsqueda
1.
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
Pharmacol Res
; 189: 106692, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36773708
2.
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs.
Nature
; 500(7464): 598-602, 2013 Aug 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-23945587
3.
Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens.
Proc Natl Acad Sci U S A
; 111(25): 9235-40, 2014 Jun 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-24928520
4.
Targeting molecular resistance in castration-resistant prostate cancer.
BMC Med
; 13: 206, 2015 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26329698
5.
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
Oncogene
; 2024 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38877132
6.
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Oncogene
; 42(9): 693-707, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36596844
7.
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
J Immunother Cancer
; 11(5)2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37147019
8.
Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Int J Cancer
; 130(11): 2693-702, 2012 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21792888
9.
The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.
Biomedicines
; 10(8)2022 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35892678
10.
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment.
Mol Cancer Ther
; 21(10): 1594-1607, 2022 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35930737
11.
Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes.
Commun Med (Lond)
; 2: 118, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36159187
12.
ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
Oncogene
; 40(35): 5379-5392, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34272475
13.
Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Mol Cancer Ther
; 19(8): 1708-1718, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32430485
14.
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Clin Cancer Res
; 26(22): 6064-6074, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32928794
15.
AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Mol Cancer Ther
; 18(10): 1875-1886, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31308078
16.
GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
Mol Cancer Ther
; 18(10): 1811-1821, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31341032
17.
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Oncogene
; 38(1): 17-32, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30072740
18.
Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Mol Cancer Ther
; 17(10): 2197-2205, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29891490
19.
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
Nat Commun
; 9(1): 4700, 2018 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30446660
20.
Development of a stress response therapy targeting aggressive prostate cancer.
Sci Transl Med
; 10(439)2018 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29720449